A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2and 6mg/m2Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

MLA

Burnett, Alan K., et al. “A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/M2and 6mg/M2Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial.” Blood, vol. 124, no. 21, Nov. 2014, p. 2308. EBSCOhost, https://doi.org/10.1182/blood.V124.21.2308.2308.

APA

Burnett, A. K., Russell, N., Hills, R. K., Cavenagh, J., Kell, J., Jones, G., Khwaja, A., McMullin, M. F., Dennis, M., Milligan, D., & Clark, R. E. (2014). A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2and 6mg/m2Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. Blood, 124(21), 2308. https://doi.org/10.1182/blood.V124.21.2308.2308

Chicago

Burnett, Alan K, Nigel Russell, Robert K. Hills, Jamie Cavenagh, Jonathan Kell, Gail Jones, Asim Khwaja, et al. 2014. “A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/M2and 6mg/M2Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial.” Blood 124 (21): 2308. doi:10.1182/blood.V124.21.2308.2308.